(19)
(11) EP 1 451 338 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.05.2012 Bulletin 2012/18

(45) Mention of the grant of the patent:
19.10.2011 Bulletin 2011/42

(21) Application number: 02789453.4

(22) Date of filing: 05.11.2002
(51) International Patent Classification (IPC): 
C12P 21/08(2006.01)
G01N 33/53(2006.01)
 C07K 16/00(2006.01)
C12M 3/00(2006.01)
(86) International application number:
PCT/US2002/035567
(87) International publication number:
WO 2003/040384 (15.05.2003 Gazette 2003/20)

(54)

RECOMBINANT ANTIBODIES FOR THE DETECTION AND NEUTRALIZATION OF ANTHRAX TOXIN

REKOMBINANTE ANTIKÖRPER ZUM NACHWEIS UND ZUR NEUTRALISIERUNG VON MILZBRANDTOXIN

ANTICORPS RECOMBINES SERVANT A LA DETECTION ET A LA NEUTRALISATION DE LA TOXINE DE L'ANTHRAX

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

(30) Priority: 05.11.2001 US 332849 P

(43) Date of publication of application:
01.09.2004 Bulletin 2004/36

(73) Proprietor: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Austin, TX 78701 (US)

(72) Inventors:
  • GEORGIOU, George The University of Texas at Austin
    Austin, TX 78712 (US)
  • IVERSON, B. L., The University of Texas at Austin
    Austin, TX 78712 (US)
  • MAYNARD, J. A., The University of Texas at Austin
    Austin, TX 78712 (US)

(74) Representative: Dehmel, Albrecht 
Dehmel & Bettenhausen Patentanwälte Herzogspitalstrasse 11
80331 München
80331 München (DE)


(56) References cited: : 
WO-A1-99/36569
US-B1- 6 329 156
 US-A- 5 601 823
   
  • MAYNARD JENNIFER ET AL: "Affinity maturation of anti-anthrax toxin SCFV" ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 216, no. 1-3, 1998, page BIOT 212, XP009069346 & 216TH NATIONAL MEETING OF THE AMERICAN CHEMICAL SOCIETY; BOSTON, MASSACHUSETTS, USA; AUGUST 23-27, 1998 ISSN: 0065-7727
  • CIRINO NICK M ET AL: "Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 67, no. 6, June 1999 (1999-06), pages 2957-2963, XP002185394 ISSN: 0019-9567
  • MAYNARD JENNIFER A ET AL: "Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity" NATURE BIOTECHNOLOGY, vol. 20, no. 6, June 2002 (2002-06), pages 597-601, XP002390004 ISSN: 1087-0156
  • KNAPPIK A ET AL: "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 296, no. 1, 11 February 2000 (2000-02-11), pages 57-86, XP004461525 ISSN: 0022-2836
  • CASTILLO J ET AL: "T7 displayed peptides as targets for selecting peptide specific scFvs from M13 scFv display libraries" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 257, no. 1-2, 1 November 2001 (2001-11-01), pages 117-122, XP004311943 ISSN: 0022-1759
  • WALORY J ET AL: "Comparison of four serological methods for the detection of diphtheria anti-toxin antibody" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 245, no. 1-2, 1 November 2000 (2000-11-01), pages 55-65, XP004218808 ISSN: 0022-1759
  • STEMMER W P C: "Rapid evolution of a protein in vitro by DNA shuffling" NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 370, 4 August 1994 (1994-08-04), pages 389-391, XP002082182 ISSN: 0028-0836
  • LITTLE S.F. ET AL.: 'Passive protection by polyclonal antibodies against bacillus anthracis infection in guinea pigs' INFECTION AND IMMUNITY vol. 65, no. 12, December 1997, pages 5171 - 5175, XP002959464
  • LITTLE S.F. ET AL.: 'Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin' INFECTION AND IMMUNITY vol. 56, no. 7, July 1988, pages 1807 - 1813, XP002959465
  • TURNBULL P.C.B. ET AL.: 'Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity' MED. MICROBIOL. IMMUNOL. vol. 177, no. 5, 1988, pages 293 - 303, XP002959466
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).